Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus.
Expert Opin Biol Ther
; 21(4): 519-528, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33085537
ABSTRACT
INTRODUCTION:
The type 1 interferon pathway is known to play a role in the immunopathology of systemic lupus erythematosus (SLE). As a result, biologic agents targeting this pathway have been developed and are currently being investigated in clinical trials. AREAS COVERED We review the biologic agents which have been developed to antagonize type I interferons in SLE. We focus on anifrolumab, a type I interferon receptor antagonist, and consider the complexities of defining efficacy in SLE clinical trials. EXPERT OPINION Anifrolumab shows promise as an addition to the SLE therapeutic armamentarium. Despite discordant results between its two phase III studies, there is a convincing suggestion of benefit in both trials to encourage the view that this approach might be effective. Data acquired thus far look particularly useful for cutaneous disease. We await data on its effect on renal, pulmonary, cardiac, and central nervous system involvement, on patient reported outcomes, and its safety and efficacy with long-term use.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antineoplásicos Imunológicos
/
Lúpus Eritematoso Sistêmico
Aspecto:
Patient_preference
Limite:
Humans
Idioma:
En
Revista:
Expert Opin Biol Ther
Assunto da revista:
BIOLOGIA
/
TERAPEUTICA
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Reino Unido